163 related articles for article (PubMed ID: 28855662)
1. TCR-like antibodies mediate complement and antibody-dependent cellular cytotoxicity against Epstein-Barr virus-transformed B lymphoblastoid cells expressing different HLA-A*02 microvariants.
Lai J; Choo JAL; Tan WJ; Too CT; Oo MZ; Suter MA; Mustafa FB; Srinivasan N; Chan CEZ; Lim AGX; Zhong Y; Chan SH; Hanson BJ; Gascoigne NRJ; MacAry PA
Sci Rep; 2017 Aug; 7(1):9923. PubMed ID: 28855662
[TBL] [Abstract][Full Text] [Related]
2. Targeting Epstein-Barr virus-transformed B lymphoblastoid cells using antibodies with T-cell receptor-like specificities.
Lai J; Tan WJ; Too CT; Choo JA; Wong LH; Mustafa FB; Srinivasan N; Lim AP; Zhong Y; Gascoigne NR; Hanson BJ; Chan SH; Chen J; MacAry PA
Blood; 2016 Sep; 128(10):1396-407. PubMed ID: 27338099
[TBL] [Abstract][Full Text] [Related]
3. TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.
Ahmed M; Lopez-Albaitero A; Pankov D; Santich BH; Liu H; Yan S; Xiang J; Wang P; Hasan AN; Selvakumar A; O'Reilly RJ; Liu C; Cheung NV
JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467338
[TBL] [Abstract][Full Text] [Related]
4. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
Khanna R; Burrows SR; Nicholls J; Poulsen LM
Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
[TBL] [Abstract][Full Text] [Related]
5. Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death.
Wittman VP; Woodburn D; Nguyen T; Neethling FA; Wright S; Weidanz JA
J Immunol; 2006 Sep; 177(6):4187-95. PubMed ID: 16951384
[TBL] [Abstract][Full Text] [Related]
6. T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen.
Burrows SR; Silins SL; Moss DJ; Khanna R; Misko IS; Argaet VP
J Exp Med; 1995 Dec; 182(6):1703-15. PubMed ID: 7500015
[TBL] [Abstract][Full Text] [Related]
7. Identification of Functional HLA-A*01:01-Restricted Epstein-Barr Latent Membrane Protein 2-Specific T-Cell Receptors.
Huisman W; Gille I; van der Maarel LE; Hageman L; Morton LT; de Jong RCM; Heemskerk MHM; Amsen D; Falkenburg JHF; Jedema I
J Infect Dis; 2022 Sep; 226(5):833-842. PubMed ID: 32808978
[TBL] [Abstract][Full Text] [Related]
8. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
[TBL] [Abstract][Full Text] [Related]
9. Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity.
Burrows SR; Silins SL; Khanna R; Burrows JM; Rischmueller M; McCluskey J; Moss DJ
Eur J Immunol; 1997 Jul; 27(7):1726-36. PubMed ID: 9247584
[TBL] [Abstract][Full Text] [Related]
10. MHC allele-specific molecular features determine peptide/HLA-A2 conformations that are recognized by HLA-A2-restricted T cell receptors.
Wang Z; Turner R; Baker BM; Biddison WE
J Immunol; 2002 Sep; 169(6):3146-54. PubMed ID: 12218132
[TBL] [Abstract][Full Text] [Related]
11. A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy.
Cho HI; Kim UH; Shin AR; Won JN; Lee HJ; Sohn HJ; Kim TG
Br J Cancer; 2018 Feb; 118(4):534-545. PubMed ID: 29360818
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus-specific cytotoxic T lymphocytes as probes of HLA polymorphism. Heterogeneity of T cell-restricting determinants associated with the serologically defined HLA-A2 antigen.
Gaston JS; Rickinson AB; Epstein MA
J Exp Med; 1983 Aug; 158(2):280-93. PubMed ID: 6193217
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic T cell recognition of allelic variants of HLA B35 bound to an Epstein-Barr virus epitope: influence of peptide conformation and TCR-peptide interaction.
Khanna R; Silins SL; Weng Z; Gatchell D; Burrows SR; Cooper L
Eur J Immunol; 1999 May; 29(5):1587-97. PubMed ID: 10359113
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
[TBL] [Abstract][Full Text] [Related]
15. Human T cell receptor-gamma delta-expressing T-cell lines recognize MHC-controlled elements on autologous EBV-LCL that are not HLA-A, -B, -C, -DR, -DQ, or -DP.
Lam V; DeMars R; Chen BP; Hank JA; Kovats S; Fisch P; Sondel PM
J Immunol; 1990 Jul; 145(1):36-45. PubMed ID: 1694208
[TBL] [Abstract][Full Text] [Related]
16. Tax and M1 peptide/HLA-A2-specific Fabs and T cell receptors recognize nonidentical structural features on peptide/HLA-A2 complexes.
Biddison WE; Turner RV; Gagnon SJ; Lev A; Cohen CJ; Reiter Y
J Immunol; 2003 Sep; 171(6):3064-74. PubMed ID: 12960332
[TBL] [Abstract][Full Text] [Related]
17. HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class I stabilization assay. Low proportion of binding motifs for several HLA class I alleles in EBNA-1.
Stuber G; Dillner J; Modrow S; Wolf H; Székely L; Klein G; Klein E
Int Immunol; 1995 Apr; 7(4):653-63. PubMed ID: 7547693
[TBL] [Abstract][Full Text] [Related]
18. Selection of a diverse TCR repertoire in response to an Epstein-Barr virus-encoded transactivator protein BZLF1 by CD8+ cytotoxic T lymphocytes during primary and persistent infection.
Silins SL; Cross SM; Elliott SL; Pye SJ; Burrows JM; Moss DJ; Misko IS
Int Immunol; 1997 Nov; 9(11):1745-55. PubMed ID: 9418135
[TBL] [Abstract][Full Text] [Related]
19. Absence of allogeneic restriction in human T-cell-mediated cytotoxicity to Epstein-Barr virus-infected target cells. Demonstration of an HLA-linked control at the effector level.
Lipinski M; Fridman WH; Tursz T; Vincent C; Pious D; Fellous M
J Exp Med; 1979 Dec; 150(6):1310-22. PubMed ID: 229186
[TBL] [Abstract][Full Text] [Related]
20. Antigenic and sequence variation in the C-terminal unique domain of the Epstein-Barr virus nuclear antigen EBNA-1.
Wrightham MN; Stewart JP; Janjua NJ; Pepper SD; Sample C; Rooney CM; Arrand JR
Virology; 1995 Apr; 208(2):521-30. PubMed ID: 7538250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
